- Home
- GOVX vs CODX Comparison
GOVX vs CODX Comparison
Compare GOVX & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- CODX
- Stock Information
- Founded
- GOVX 2001
- CODX 2013
- Country
- GOVX United States
- CODX United States
- Employees
- GOVX N/A
- CODX N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- CODX Medical/Dental Instruments
- Sector
- GOVX Health Care
- CODX Health Care
- Exchange
- GOVX Nasdaq
- CODX Nasdaq
- Market Cap
- GOVX 16.8M
- CODX 15.6M
- IPO Year
- GOVX N/A
- CODX 2017
- Fundamental
- Price
- GOVX $0.41
- CODX $0.38
- Analyst Decision
- GOVX Strong Buy
- CODX Strong Buy
- Analyst Count
- GOVX 2
- CODX 3
- Target Price
- GOVX $7.00
- CODX $2.25
- AVG Volume (30 Days)
- GOVX 524.6K
- CODX 3.2M
- Earning Date
- GOVX 11-13-2025
- CODX 11-13-2025
- Dividend Yield
- GOVX N/A
- CODX N/A
- EPS Growth
- GOVX N/A
- CODX N/A
- EPS
- GOVX N/A
- CODX N/A
- Revenue
- GOVX $3,353,560.00
- CODX $507,892.00
- Revenue This Year
- GOVX N/A
- CODX N/A
- Revenue Next Year
- GOVX N/A
- CODX $31.58
- P/E Ratio
- GOVX N/A
- CODX N/A
- Revenue Growth
- GOVX 8.52
- CODX N/A
- 52 Week Low
- GOVX $0.37
- CODX $0.23
- 52 Week High
- GOVX $3.01
- CODX $1.55
- Technical
- Relative Strength Index (RSI)
- GOVX 35.66
- CODX 49.84
- Support Level
- GOVX $0.37
- CODX $0.32
- Resistance Level
- GOVX $0.44
- CODX $0.38
- Average True Range (ATR)
- GOVX 0.03
- CODX 0.04
- MACD
- GOVX -0.00
- CODX -0.00
- Stochastic Oscillator
- GOVX 26.59
- CODX 58.04
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.